Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BT-007 CAR-T in R/R T-LBL
NCT05554575Phase 1Unknown
- Sponsor
- Bioceltech Therapeutics, Ltd.
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BT-007 CD7 CAR-T cells in T cell lymphoblastic lymphoma (T-LBL), sponsored by Bioceltech Therapeutics, Ltd. Primary endpoint: Objective Response Rate at Month 24. Status: unknown.
02
Drugs
BT-007 CD7 CAR-T cells
03
Conditions
T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT05554575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554575.